ABVC BioPharma, Inc. (ABVC)Healthcare | Biotechnology | Fremont, United States | NasdaqCM
0.83 USD
+0.03
(4.311%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.87 +0.04 (4.819%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:50 a.m. EDT
The fundamental reality here is stark: this biotech stock has suffered a catastrophic multi-year decline, dropping over 99% from its 2016 highs, driven by years of shrinking valuations and negative earnings. Despite a recent year-over-year price surge, the underlying business remains in distress with a negative return on equity, significant debt, and no reported revenue. The recent price action is not a sign of a turnaround but rather a reaction to a specific corporate restructuring event—the planned spin-off of BioKey—which has temporarily lifted the share price but leaves the core entity with a precarious balance sheet. The lack of analyst coverage and the 'none' recommendation key confirm that traditional investors see no path to recovery. While the options market is pricing in a dramatic binary event, the odds favor continued volatility and potential further downside given the company's inability to generate cash or profits. This is a speculative vehicle for a single event, not a viable investment for capital preservation or growth. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.146798 |
| AutoETS | 0.146798 |
| MSTL | 0.150521 |
| AutoARIMA | 0.164027 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 7.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.149 |
| Excess Kurtosis | 0.36 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.533 |
| Market Cap | 22,123,122 |
| Forward P/E | -1.89 |
| Beta | 0.63 |
| Previous Name | American BriVision (Holding) Corporation |
| Website | https://www.abvcpharma.com |
As of Aug. 22, 2026, 1:50 a.m. EDT: Speculators are positioning asymmetrically for a massive gap-up event rather than steady appreciation. Call volume is heavily skewed toward deep out-of-the-money strikes ($7.50) expiring in late August and February 2027, suggesting a bet on a binary catalyst like a spin-off completion or major trial readout. Conversely, put buyers are concentrated in November 2026 and February 2027, creating a 'straddle' or 'strangle' setup where traders are betting on extreme volatility in either direction, though the call side shows slightly more aggressive volume relative to the strike distance.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7084249 |
| Address1 | 44,370 Old Warm Springs Boulevard |
| All Time High | 7,165,605.0 |
| All Time Low | 0.343949 |
| Ask | 1.06 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 97,930 |
| Average Daily Volume3 Month | 138,854 |
| Average Volume | 138,854 |
| Average Volume10Days | 97,930 |
| Beta | 0.63 |
| Bid | 0.588 |
| Bid Size | 2 |
| Book Value | 0.404 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.83 |
| Current Ratio | 0.072 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.8499 |
| Day Low | 0.8101 |
| Debt To Equity | 23.533 |
| Display Name | ABVC BioPharma |
| Dividend Date | 1,557,273,600 |
| Earnings Timestamp End | 1,755,518,400 |
| Earnings Timestamp Start | 1,754,996,340 |
| Ebitda | -6,491,358 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.05 |
| Enterprise Value | 26,292,064 |
| Eps Forward | -0.44 |
| Eps Trailing Twelve Months | -0.3 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.20666 |
| Fifty Day Average Change | -0.37666005 |
| Fifty Day Average Change Percent | -0.31215093 |
| Fifty Two Week Change Percent | -70.84249 |
| Fifty Two Week High | 3.4 |
| Fifty Two Week High Change | -2.5700002 |
| Fifty Two Week High Change Percent | -0.7558824 |
| Fifty Two Week Low | 0.707 |
| Fifty Two Week Low Change | 0.122999966 |
| Fifty Two Week Low Change Percent | 0.17397448 |
| Fifty Two Week Range | 0.707 - 3.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,100,097,000,000 |
| Float Shares | 21,095,690 |
| Forward Eps | -0.44 |
| Forward P E | -1.8863636 |
| Free Cashflow | 1,563,662 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 16 |
| Fullday Change | 0.0343 |
| Fullday Change Percent | 4.31067 |
| Fullday Price | 0.87 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18114 |
| Held Percent Institutions | 0.04089 |
| Implied Shares Outstanding | 26,654,365 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-08-03 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,690,243,200 |
| Last Split Factor | 1:10 |
| Long Business Summary | ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. |
| Long Name | ABVC BioPharma, Inc. |
| Market | us_market |
| Market Cap | 22,123,122 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_325748154 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -7,106,633 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 21,208,878 |
| Open | 0.84 |
| Operating Cashflow | -2,690,948 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 668 0881 |
| Post Market Change | 0.04000002 |
| Post Market Change Percent | 4.8192797 |
| Post Market Price | 0.87 |
| Post Market Time | 1,787,959,805 |
| Prev Name | American BriVision (Holding) Corporation |
| Previous Close | 0.7957 |
| Price Hint | 4 |
| Price To Book | 2.0544553 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.023 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0343 |
| Regular Market Change Percent | 4.31067 |
| Regular Market Day High | 0.8499 |
| Regular Market Day Low | 0.8101 |
| Regular Market Day Range | 0.8101 - 0.8499 |
| Regular Market Open | 0.84 |
| Regular Market Previous Close | 0.7957 |
| Regular Market Price | 0.83 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 94,038 |
| Return On Assets | -0.22850001 |
| Return On Equity | -0.69858 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 26,654,365 |
| Shares Percent Shares Out | 0.0161 |
| Shares Short | 429,447 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 465,232 |
| Short Name | ABVC Biopharma, Inc. |
| Short Percent Of Float | 0.0197 |
| Short Ratio | 4.39 |
| Source Interval | 15 |
| State | CA |
| Symbol | ABVC |
| Total Cash | 94,364 |
| Total Cash Per Share | 0.004 |
| Total Debt | 2,887,361 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.571855 |
| Two Hundred Day Average Change | -0.74185497 |
| Two Hundred Day Average Change Percent | -0.47196147 |
| Type Disp | Equity |
| Volume | 94,038 |
| Website | https://www.abvcpharma.com |
| Zip | 94,538 |